Skip to main content
Caplight Logo









Libo Pharma Corp.

Libo Pharma Corp.

Private
TaipeiHealthcare & Life Scienceshttps://libopharma.com/

Last Round

Series C

Jul 21, 2025

Total Funding Raised

$29.33M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Libo Pharma Corp. is a biotechnology company that operates as a biopharmaceutical innovation incubator developing novel protein therapeutics and immunotherapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Application

Keywords

NRDOvirtual biotechdrug developmentclinical developmentoncologyimmunotherapeuticsasset-centric biotechcytokine therapymedical countermeasureInterleukin-12IL-12Acute Radiation SyndromeARSCutaneous T-cell lymphomaCTCLdrug licensinghematologyregenerative medicineAI in drug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Libo Pharma Corp. Comparables

Compare Libo Pharma Corp. with similar companies based on industry and business-model similarity.

Libo Pharma Corp. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Statera BioPharma, Inc.
76%
Partner Therapeutics
74%
PharmaEngine, Inc.
71%

Libo Pharma Corp. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CJul 21, 2025
Series BMar 1, 2024
SeedJun 1, 2017

Libo Pharma Corp. Investors

Notable investors and investment history

Libo Pharma Corp. investors
InvestorRounds
CTBC Venture CapitalSeries C
Beiley BiofundSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors increased 160% MoM, reaching 1.9K.

  • Jul 27, 2026

    Grew 29% QoQ, from 14 to 18 employees.

Libo Pharma Corp. Filings

Explore SEC and related filing metadata, where available.

Libo Pharma Corp. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Libo Pharma Corp.'s valuation, stock price, and market status.

Is Libo Pharma Corp. a public or private company?

Libo Pharma Corp. is a private company.

What is the current stock price of Libo Pharma Corp.?

Libo Pharma Corp. is a private company with no public stock price. No recent secondary market data is available.

How much is Libo Pharma Corp. worth (valuation)?

Valuation information for Libo Pharma Corp. is not publicly available.

Can I buy Libo Pharma Corp. stock?

Libo Pharma Corp. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Libo Pharma Corp.'s last funding round?

Funding round information for Libo Pharma Corp. is not publicly available.

Who are the main investors in Libo Pharma Corp.?

Investor information for Libo Pharma Corp. is not publicly disclosed.

Will Libo Pharma Corp. IPO soon?

No public IPO plans have been announced for Libo Pharma Corp..

How can I track Libo Pharma Corp. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Libo Pharma Corp.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersTaipei
Employee Range15
Year Founded2017
Last FundingJul 21, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?